PE20180931A1 - Metodo de cristalizacion y biodisponibilidad - Google Patents

Metodo de cristalizacion y biodisponibilidad

Info

Publication number
PE20180931A1
PE20180931A1 PE2018000403A PE2018000403A PE20180931A1 PE 20180931 A1 PE20180931 A1 PE 20180931A1 PE 2018000403 A PE2018000403 A PE 2018000403A PE 2018000403 A PE2018000403 A PE 2018000403A PE 20180931 A1 PE20180931 A1 PE 20180931A1
Authority
PE
Peru
Prior art keywords
biodavailability
api
composition
zoledronic acid
molecular complex
Prior art date
Application number
PE2018000403A
Other languages
English (en)
Spanish (es)
Inventor
Mazen Hanna
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58289727&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20180931(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of PE20180931A1 publication Critical patent/PE20180931A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2018000403A 2015-09-18 2016-09-19 Metodo de cristalizacion y biodisponibilidad PE20180931A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562220404P 2015-09-18 2015-09-18

Publications (1)

Publication Number Publication Date
PE20180931A1 true PE20180931A1 (es) 2018-06-08

Family

ID=58289727

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018000403A PE20180931A1 (es) 2015-09-18 2016-09-19 Metodo de cristalizacion y biodisponibilidad

Country Status (12)

Country Link
US (1) US20190083407A1 (enExample)
EP (1) EP3362071A4 (enExample)
JP (1) JP2018527392A (enExample)
KR (1) KR20180053384A (enExample)
CN (1) CN108601791A (enExample)
AU (1) AU2016324482A1 (enExample)
CA (1) CA2997378A1 (enExample)
CL (1) CL2018000705A1 (enExample)
CO (1) CO2018003558A2 (enExample)
MX (1) MX2018002627A (enExample)
PE (1) PE20180931A1 (enExample)
WO (1) WO2017049294A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2769633C (en) 2009-07-31 2017-06-06 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability
US10377708B2 (en) 2017-12-05 2019-08-13 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
CN118593482A (zh) 2017-12-05 2024-09-06 赛诺维信制药公司 非外消旋混合物及其用途
CN108440449B (zh) * 2018-04-17 2021-05-07 中国海洋大学 一种氢氯噻嗪与脯氨酸的共晶及其制备方法
CN108558791B (zh) * 2018-06-08 2021-05-07 中国海洋大学 一种乙酰唑胺与脯氨酸的共晶及其制备方法
CN108570051B (zh) * 2018-07-20 2021-02-02 中国科学院上海药物研究所 呋塞米-氨苯蝶啶盐、晶型i及其制备方法和应用
CN108794418A (zh) * 2018-09-18 2018-11-13 中国药科大学 一种缬沙坦烟酰胺共无定形物
CN109568284B (zh) * 2018-12-29 2020-04-24 广东中润药物研发有限公司 一种替诺福韦艾拉酚胺肠溶片及其制备方法
CN109776430B (zh) * 2019-02-01 2022-05-13 福建农林大学 一种磺胺二甲嘧啶共晶及其制备方法
JP2022535893A (ja) 2019-06-04 2022-08-10 サノビオン ファーマシューティカルズ インク 放出調節製剤およびその使用
CN110372575A (zh) * 2019-07-10 2019-10-25 复旦大学 一种二氢吡啶钙拮抗剂共晶体及其制备方法和应用
CN111053755B (zh) * 2019-12-31 2022-03-29 金日制药（中国）有限公司 一种高渗透性的头孢克肟胶囊制剂制备方法
WO2022162604A1 (ko) * 2021-01-28 2022-08-04 (주)아이엠디팜 카모스타트 및 니클로사마이드를 포함하는 공결정, 이를 포함하는 약학 조성물 및 이의 제조 방법
CN113181179A (zh) * 2021-04-08 2021-07-30 深圳市泰力生物医药有限公司 一种二氢吡啶类钙拮抗剂盐组合物及其制备方法和应用
KR102544543B1 (ko) * 2021-04-29 2023-06-16 대봉엘에스 주식회사 L,d-엘도스테인의 개별적 공결정화물
WO2024151838A1 (en) * 2023-01-11 2024-07-18 Board Of Regents, The University Of Texas System Co-crystals with thin-film freeze-drying process to enhance delivery

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040220264A1 (en) * 2003-03-17 2004-11-04 Yu Ruey J Bioavailability and improved delivery of acidic pharmaceutical drugs
EP1567533B1 (en) * 2003-07-03 2009-03-11 Teva Pharmaceutical Industries Ltd. Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
AR075613A1 (es) * 2009-02-25 2011-04-20 Merrion Res Iii Ltd Composicion y suministro de drogas de bifosfonato. metodo de tratamiento
US8980868B2 (en) * 2009-07-31 2015-03-17 Thar Pharmaceuticals, Inc. Oral forms of a phosphonic acid derivative
CA2769633C (en) * 2009-07-31 2017-06-06 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
DK2531200T3 (en) * 2010-02-06 2017-09-11 Gruenenthal Gmbh COSTALLIZATION PROCEDURE AND BIOTA ACCESSIBILITY
KR20120105738A (ko) * 2011-03-16 2012-09-26 현대약품 주식회사 장용코팅된 경구용 제제
US20130303486A1 (en) * 2012-05-14 2013-11-14 Herriot Tabuteau Compositions Comprising Zoledronic Acid or Related Compounds for Relieving Pain Associated with Arthritis
US8802658B2 (en) * 2012-05-14 2014-08-12 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
US20140349974A1 (en) * 2014-08-12 2014-11-27 Antecip Bioventures Ii Llc Zoledronic acid dosage forms for the treatment of pain
US20140348916A1 (en) * 2014-08-11 2014-11-27 Antecip Bioventures Ii Llc Treatment of Pain with Oral Dosage Forms Comprising Zoledronic Acid and An Enhancer

Also Published As

Publication number Publication date
US20190083407A1 (en) 2019-03-21
CA2997378A1 (en) 2017-03-23
CL2018000705A1 (es) 2018-08-24
KR20180053384A (ko) 2018-05-21
WO2017049294A1 (en) 2017-03-23
EP3362071A4 (en) 2019-07-17
CO2018003558A2 (es) 2018-07-19
CN108601791A (zh) 2018-09-28
AU2016324482A1 (en) 2018-03-29
EP3362071A1 (en) 2018-08-22
MX2018002627A (es) 2018-12-17
JP2018527392A (ja) 2018-09-20

Similar Documents

Publication Publication Date Title
PE20180931A1 (es) Metodo de cristalizacion y biodisponibilidad
IL264413B (en) Preparations containing fibers obtained electrohydrodynamically for delivering specific doses of active substance to the skin or mucous membrane
NI201600051A (es) Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores
CL2015002164A1 (es) Formulación combinada de dos compuesos antivirales.
BR112018003212A2 (pt) diacereína ou seus análogos para inibir a expressão de asc, expressão de nlrp3 e / ou formação de complexo inflamassoma nlrp3
MX2017004471A (es) Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística.
DOP2017000307A (es) Formulación sólida oral que contiene irinotecán y método de preparación de la misma.
CY1124734T1 (el) Μορφες δοσολογιας αυξητικης ορμονικης μακρας δρασης
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
CY1122113T1 (el) Φαρμακευτικες συνθεσεις για τη θεραπεια του ελικοβακτηριδιου του πυλωρου
EA201690679A1 (ru) Стабильная фармацевтическая композиция, содержащая амлодипин и валсартан
MX388251B (es) Nuevo anticuerpo que se una a tfpi y composicion que comprende el mismo.
DOP2016000007A (es) Pirazolpiridinas sustituidas
CY1122387T1 (el) Διπλης χρησης δισκια στοματικης φαρμακευτικης συνθεσης θειικων αλατων και μεθοδοι χρησης αυτων
MX2018004304A (es) DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß.
CL2014002845A1 (es) Compuestos derivados de pirazol inhibidores de sglt1; metodo para tratar la diabetes; composicion farmaceutica; uso del compuesto para el tratamiento de la diabetes tipo 1 y tipo 2.
BR112017004304A2 (pt) composições de pteroestilbeno tópicas para uso em tratamento de perda de função de barreira na pele induzidas por uv
EA201692493A1 (ru) Противомикробные фармацевтические композиции со способностями ингибирования множественной лекарственной устойчивости
AR094634A1 (es) Formulación de cápsulas de ácido 5-aminosalicílico
UY36598A (es) Composición para el tratamiento de neuropatías y/o dolor neuropático
UY33806A (es) ?compuestos novedosos de imidazoquinolina, composiciones que los contienen y su uso en el tratamiento de enfermedades mediadas por tlr7?
GR1008227B (el) Σταθερο φαρμακευτικο σκευασμα ενος βενζιμιδαζολικου αναστολεα της αντλιας πρωτονιων και μεθοδος για την παρασκευη αυτου
PE20181374A1 (es) Formulacion de combinacion farmaceutica
TN2016000479A1 (en) Nitisinone dosing regimens for the treatment of alkaptonuria.
HK1241310A1 (en) Topical pterostilbene compositions for use in treating uv-induced loss of barrier function in skin